ABT.KZ · Abbott Laboratories
95.00
USDUnlock stock Insights
Create a free account to unlock price targets, recommendations, and commentary.
Overview
Market Cap
n/a
PE
33.70
EV/EBITDA
19.7
DIV Yield
1.9%
Payout Ratio
65%
MQV Rating
5Very Weak
As at 21/10/2026 12:00:00 AM
Price Chart
Description
- All-Companies
Key Fundamentals
EPS 3 yr Growth
-5.20%
EBITDA Margin
25.70%
Operating Cashflow
$9,566m
Free Cash Flow Return
15.40%
ROIC
10.50%
Interest Coverage
21.70
Quick Ratio
1.20
Performance
52 weeks range
Low 90 - 144.1
Trade Value (12mth)
US$35.00
1 week
-13.64%
1 month
-19.49%
YTD
-23.39%
1 year
0%
All time high
144.10
Additional Data
Shares Outstanding (Fully Diluted)
1,738m
HALO Sector
Healthcare
Next Company Report Date
N/A
Next Ex Dividend Date
15-Oct-26
Next Dividend Pay Date
16-Nov-26
Reporting Currency
USD
Short Sell (% of issue)
0.00
Health Scores
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Very Strong
Halo Model
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Valuation
Value
Consensus
Yield
Key Stakeholders
| Name | Title |
| Daniel J. Starks | Individual |
| Wellcome Trust Ltd. (Direct Investments) | Operating Division |
| Robert B. Ford | Individual |
| Hubert L. Allen | Individual |
| Daniel Gesua Sive Salvadori | Individual |
